AMH Predicts Postchemotherapy Menopause in Premenopausal Breast Cancer Patients

NCT06313476 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 153

Last updated 2024-03-15

No results posted yet for this study

Summary

To determine the accuracy of AMH postchemotherapy in predicting permanent menopause after chemotherapy in breast cancer patients who did not use OFS before menopause

Conditions

Sponsors & Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
59 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2026-04-30
Completion
2026-04-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06313476 on ClinicalTrials.gov